Avoiding permanent atrial fibrillation: treatment approaches to prevent disease progression

Vasc Health Risk Manag. 2014:10:1-12. doi: 10.2147/VHRM.S49334. Epub 2013 Dec 16.

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia and a major global public health problem due to its associated morbidity, including stroke and heart failure, diminished quality of life, and increased mortality. AF often presents initially in a paroxysmal form and may progress to a more sustained form over time. Evidence from randomized controlled trials suggests that there may be no mortality benefit to using a rhythm control approach in comparison with rate control of AF. Nevertheless, sustained forms of AF may be associated with increased symptoms and cardiovascular morbidity, and consequently they remain an additional target for therapy. The present review evaluates the clinical correlates of arrhythmia progression and risk stratification techniques available to assess probability of AF progression. Further, currently available management options for arrhythmia control in AF are evaluated and their therapeutic effect and efficacy on disease progression are explored.

Keywords: atrial fibrillation; permanent; prevention; progression.

Publication types

  • Review

MeSH terms

  • Anti-Arrhythmia Agents / adverse effects
  • Anti-Arrhythmia Agents / therapeutic use*
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / mortality
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / therapy*
  • Catheter Ablation* / adverse effects
  • Catheter Ablation* / mortality
  • Disease Progression
  • Heart Failure / etiology
  • Heart Failure / mortality
  • Heart Failure / prevention & control*
  • Heart Rate / drug effects
  • Humans
  • Incidence
  • Prevalence
  • Preventive Health Services*
  • Risk Factors
  • Stroke / etiology
  • Stroke / mortality
  • Stroke / prevention & control*
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents